Blog

A new interesting article has been published in PLoS One. 2019 Jul 2;14(7):e0218890. doi: 10.1371/journal.pone.0218890. eCollection 2019. and titled:

Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector.

Authors of this article are:

Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP.

A summary of the article is shown below:

BACKGROUND: Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India.METHODS: Using a microsimulation model, we compared four TB diagnostic strategies for HIV-negative adults with presumptive TB: (1) sputum smear microscopy in designated microscopy centers (DMCs) (SSM); (2) Xpert MTB/RIF in DMCs (Xpert); (3) Truenat in DMCs (Truenat DMC); and (4) Truenat for point-of-care testing in primary healthcare facilities (Truenat POC). We projected life expectancy, costs, incremental cost-effectiveness ratios (ICERs), and 5-year budget impact of deploying Truenat POC in India’s public sector. We defined a strategy “cost-effective” if its ICER was Check out the article’s website on Pubmed for more information:

[link-preview url=https://www.ncbi.nlm.nih.gov/pubmed/31265470 forceshot=true]

This article is a good source of information and a good way to become familiar with topics such as: n/a.

New Chemicals from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT


New Antibodies from MOLECULAR DEPOT


New Research Kits from MOLECULAR DEPOT